New Delhi, Torrent Pharmaceuticals Ltd on Friday reported 56.45 per cent rise in March quarter consolidated net profit to Rs 449 crore on the back of higher revenue.
Torrent Pharmaceuticals said in a regulatory filing that the company had posted a consolidated net profit of Rs 287 crore in the same period last fiscal.
Consolidated revenue from operations stood at Rs 2,745 crore in Q4FY24, compared to Rs 2,491 crore in the year-ago period, it said.
The company said India revenue was up 10 per cent at Rs 1,380 crore, while Brazi revenue was up 17 per cent at Rs 372 crore, and Germany revenue was at Rs 280 crore, up 11 per cent in the quarter. ,
On the other hand, revenue from the US business was down 6 per cent at Rs 262 crore, as I mentioned.
Total expenses in the quarter under review were higher at Rs 2,145 crore compared to Rs 2,067 crore in the same period a year ago.
Torrent Pharma said its board has recommended a final dividend of Rs 6 per equity share of Rs 5, subject to shareholders' approval.
Further, the Board has also recommended obtaining competent approval from the shareholder to raise up to Rs 5,000 crore by issuing equity shares including convertible bonds/debentures through Qualified Institutional Placement (QIP) and or any other means.
The company said consolidated net profit for the financial year ending March 31, 2024, stood at Rs 1,65 crore, compared to Rs 1,245 crore in the previous year.
Consolidated revenue from operations in FY2014 stood at Rs 10,728 crore compared to Rs 9,620 crore in FY2013.
Torrent Pharmaceuticals said in a regulatory filing that the company had posted a consolidated net profit of Rs 287 crore in the same period last fiscal.
Consolidated revenue from operations stood at Rs 2,745 crore in Q4FY24, compared to Rs 2,491 crore in the year-ago period, it said.
The company said India revenue was up 10 per cent at Rs 1,380 crore, while Brazi revenue was up 17 per cent at Rs 372 crore, and Germany revenue was at Rs 280 crore, up 11 per cent in the quarter. ,
On the other hand, revenue from the US business was down 6 per cent at Rs 262 crore, as I mentioned.
Total expenses in the quarter under review were higher at Rs 2,145 crore compared to Rs 2,067 crore in the same period a year ago.
Torrent Pharma said its board has recommended a final dividend of Rs 6 per equity share of Rs 5, subject to shareholders' approval.
Further, the Board has also recommended obtaining competent approval from the shareholder to raise up to Rs 5,000 crore by issuing equity shares including convertible bonds/debentures through Qualified Institutional Placement (QIP) and or any other means.
The company said consolidated net profit for the financial year ending March 31, 2024, stood at Rs 1,65 crore, compared to Rs 1,245 crore in the previous year.
Consolidated revenue from operations in FY2014 stood at Rs 10,728 crore compared to Rs 9,620 crore in FY2013.